This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
In the mid-1990s the NHS in the UK took the bold step of making this a universal feature of result delivery to general practice (GPs) and embarked on two linked projects to achieve this. In the first, the Pathology Messaging Enabler Project, standards were defined and infrastructure installed to link 200 laboratory systems to 8,500 GP systems. In the second project, the Pathology Messaging Implementation Project, these standards and the associated software was rolled out. By 2004 more than 35 million results messages were being transmitted each year and in 2007 some 50 million such messages were safely and securely delivered. During the 12 months to July 2023, 1.88 Billion discrete new EPR items added to electronic patient records held by UK GPs were expressed using a code from within the PBCL, accompanied (usually) by a value and a unit of measurement. The PMIP EDIFACT+PBCL system remains the prevailing technology supporting all GP laboratory requesting and resulting across the entire UK, but the strategic national intent since the early 2020s has been to migrate all live GP systems to FHIR and the Unified Test List, a new and bespoke national extension of SNOMED CT offering greater detail. Although it is hoped this migration will remove the discordant standards used between UK primary and secondary care, as of August 2024 the migration has yet to begin.
In May 2006, Valve announced a trilogy of episodic games that would continue the Half-Life 2 story, with the final episode planned for release by Christmas 2007. Valve's president, Gabe Newell, said the approach would allow Valve to release products more quickly after the six-year Half-Life 2 development, and that he considered the trilogy the equivalent of Half-Life 3. According to Newell, where Half-Life saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. Episode One was released on June 1, 2006. The player controls Freeman as he and Alyx escape City 17 before a dark energy reactor core destroys it. It introduced several graphical effects, including new lighting features and more advanced facial animation. The story focuses on Alyx. Episode One received a generally positive critical reaction, although the short length was a common point of criticism.
== Interactions == Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. It may also potentiate the CNS depressant effects of alcohol. It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbital) and itself. It may also interact with:
=== Infrastructure === As Minister, McNaughton introduced Bill 32, the Access to Natural Gas Act, in the fall of 2018. It was passed into law that December. Bill 32 was intended to make it possible to expand access to natural gas throughout rural and Northern Ontario, including First Nations communities. Premier Ford said in a statement released on September 17, 2018, that "cancelling the cap-and-trade carbon tax" had caused the price of natural gas to decrease in Ontario. Premier Ford announced the new legislation and explained how it differed from the previous government's 2017 taxpayer-funded $100 million Natural Gas Grant Program—through which—according to Premier Ford, "private sector companies were limited from participating in natural gas expansion, portions of which were instead managed by the [Natural Gas Grant Program]." Bill 32, the Access to Natural Gas Act passed into law in 2018 to "encourage more private gas distributors to partner with communities to develop projects that expand access to affordable and efficient natural gas." On September 18, 2018, the city of North Bay learned that the Natural Gas Grant Program funding of over $8.6 million had been cancelled for a natural gas project that would have extended "services to as many as 350 homes in the north shore area of Trout Lake." In January 2019, Minister McNaughton announced that the Ford government would provide $27 million to Northeast Midstream towards the construction of their Nipigon LNG gas plant.
=== Designation process === The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive. The most recent grant application prepared by MD Anderson Cancer Center took 24 months to prepare and ran to 2,963 pages. Cancer centers must renew their status with the NIH every 5 years. The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director. Independent or freestanding cancer centers are entities unto themselves and are not considered to be part of a larger institution or university. The center’s administration controls all space, appointments and budgets. These institutions may have university affiliations, but they remain administratively and financially distinct. The NCI also supports Consortium Centers, wherein scientists and clinicians from multiple institutions enter into formal agreements to expand cancer research programs. Importantly, Consortium Partners are not themselves considered NCI-designated. The NCI has strict guidelines on how Consortium Partners can refer to their relationship with their parent Consortium Center.
Sources: en.wikipedia.org
=== United Kingdom === In the United Kingdom, following a local newspaper story in October 2005, a parliamentary Early Day Motion was raised calling for Salvia divinorum to be banned there. However, it only received 11 signatures. A second motion raised in October 2008 attracted 18 signatures, and it was reported that Mann had also written to Jacqui Smith, then Home Secretary. The Advisory Council on the Misuse of Drugs, the independent body that advises UK government on drugs, was asked to investigate further. On the 28 January 2016, the Psychoactive Substances Act 2016 was passed. The act came into force on 26 May 2016, across the entire United Kingdom, making S. divinorum illegal to possess with intent to supply, possess on custodial premises, import for human consumption, or produce for human consumption. The two sponsors for the bill were Conservative House of Lords member Michael Bates and Conservative MP Theresa May.
=== Modelling metabolism === There are several ways metabolism can be modeled. For some models, a linear excretion rate is preferred. This can be accomplished with a simple differential equation. Otherwise a Michaelis-Menten equation, as follows, is generally appropriate for a more accurate result.
=== Biophysical limitations === The tree of the African locust bean requires "between 0-300 metres of altitude, a mean annual rainfall of between 400-700 millimetres and a mean annual temperature of about 24-28°C." It prefers well-drained, thick clay soils but can also be found on shallow, thin sandy soils.
As such, Hamilton argues that the focus of this teaching is on our subjective experience, not on anything external to it. Collett Cox also sees the theory of dependent origination found in the early Buddhist sources as an analysis of how suffering is produced in our experience. Cox states that it is only in later Abhidharma literature that dependent origination became an abstract theory of causation. A similar interpretation has been put forth by Bhikkhu Buddhadasa who argues that, in the list of the twelve nidanas, jati and jaramarana refer not to rebirth and physical death, but to the birth and death of our self-concept, the "emergence of the ego". According to Buddhadhasa,
Stephen B. H. Kent (born December 12, 1945, Wellington, New Zealand). Stephen Kent is best known for establishing the field of modern chemical protein synthesis. At The Scripps Research Institute in the early 1990s he introduced the chemical ligation concept: condensation of unprotected peptides, for the total synthesis of protein molecules. With his student Philip Dawson, he developed the native chemical ligation reaction for the covalent condensation of unprotected peptide chains linked by native peptide bonds Kent pioneered the study of mirror image protein molecules. His laboratory experimentally demonstrated that chemical synthesis of a protein's polypeptide chain using mirror-image D-amino acids, after folding results in a mirror-image D-protein molecule which, if the D-protein is an enzyme, will catalyze a chemical reaction with mirror-image stereospecificity. Kent was the inventor of mirror image drug discovery, the use of mirror image protein targets to discover novel chiral drug leads, and his laboratory pioneered the systematic development of D-protein molecules as candidate therapeutics. At the University of Chicago, Kent and his junior colleagues pioneered the elucidation of novel protein structures by quasi-racemic & racemic crystallography .
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.